Diffuse Large B Cell Lymphoma in patients 80 years and older: Worse Survival After Treatment Without Increased Relapse Rates.

Age is an adverse prognostic factor in diffuse large B cell lymphoma (DLBCL), but there are limited data on the outcomes of patients ≥ 80 years, including those treated with dose reduced chemoimmunotherapy. We conducted a retrospective analysis of 542 patients, 85 (16%) were ≥ 80 years of age. Although this very elderly group had more frequent comorbidities and decreased performance status, 89% received therapy. Four-year PFS was 42% vs. 61% (p

Source: Clinical Lymphoma, Myeloma and Leukemia - June 24, 2021 Category: Hematology Authors: Madison Keenan, Akiva Diamond, Kirsten Boughan, Brenda Cooper, Molly Gallogly, Ehsan Malek, Leland Metheny, Timothy O'Brien, Folashade Otegbeye, Benjamin Tomlinson, Marcos de Lima, Paolo F. Caimi Source Type: research